Bright Minds Biosciences (DRUG) vs Kamada (KMDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kamada (KMDA) has outperformed Bright Minds Biosciences (DRUG) over the past year, gaining 16.6% versus a loss of 5.8%. Over five years, KMDA leads with a +47.5% price change compared with +40.0% for DRUG. Bright Minds Biosciences is the larger company by market cap ($533.2 million vs $466.3 million), about 1.1 times the size.
Kamada pays a dividend yielding 3.09%, while Bright Minds Biosciences does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DRUG | KMDA |
|---|---|---|
| Share price | $54.05 | $8.08 |
| Market cap | $533.15M | $466.30M |
| 1-day change | +3.94% | +3.92% |
| YTD return | -33.37% | +14.45% |
| 1-year return | -5.80% | +16.59% |
| 5-year return | +39.97% | +47.53% |
| P/E ratio (TTM) | — | 21.26 |
| Forward P/E | — | 14.01 |
| EPS (TTM) | $-2.05 | $0.38 |
| Dividend yield | 0.00% | 3.09% |
| Annual dividend | $0.00 | $0.25 |
| 52-week high | $123.75 | $9.35 |
| 52-week low | $47.23 | $6.55 |
| Distance from 52-week high | -56.32% | -13.58% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +181.17% | +67.08% |
| Average volume | 159.01K | 118.61K |
| Shares outstanding | 9.86M | 57.71M |
| Employees | 26 | 462 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KMDA has outperformed DRUG by 22.4 percentage points over the past year.
- Kamada offers a meaningfully higher dividend yield (3.09% vs 0.00%).
About Bright Minds Biosciences
DRUG stock →Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
About Kamada
KMDA stock →Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 462 employees
DRUG vs KMDA FAQ
Which is bigger, Bright Minds Biosciences or Kamada?
Bright Minds Biosciences (DRUG) is larger, with a market capitalization of $533.15M compared with $466.30M for Kamada (KMDA).
Which stock has performed better over the past year, DRUG or KMDA?
KMDA returned +16.59% over the past 12 months, compared with -5.80% for DRUG (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Bright Minds Biosciences or Kamada?
Kamada pays a dividend yielding 3.09%, while Bright Minds Biosciences does not currently pay a regular dividend.
Are Bright Minds Biosciences and Kamada in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.